Speakers


Check out the mini-curriculum, just click on the Speaker’s name:


International Speakers

ANTHONY G. LETAI
DUNG LE 
DUNG LE
Dr. Dung Le is an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University in Baltimore, Maryland. She is a member of the Gastrointestinal Malignancies Division of Medical Oncology.
Dr. Le received her undergraduate degree at Yale University and underwent internal medicine and oncology fellowship training at Johns Hopkins University. Her research interests include novel approaches to patients with gastrointestinal malignancies. Her main research focuses are on combination immunotherapy strategies or the use of predictive biomarkers to improve responses to immunotherapy. She has helped lead the development of programmed death-1 (PD-1) blockade in tumors with mismatch repair deficiency across disease types which led to the first biomarker selection tissue agnostic FDA approval. She is also testing multiple combinations with immune checkpoint blockade in the hopes of improving responses to immunotherapy in gastrointestinal malignancies.

EDUARDO M. SOTOMAYOR 
EDUARDO M. SOTOMAYOR
Dr. Sotomayor received his MD degree from Federico Villarreal National University School of Medicine in Lima, Peru. He completed a residency training in Internal Medicine at Jackson Memorial Hospital/University of Miami School of Medicine in Florida, followed by a fellowship in Medical Oncology at Johns Hopkins University in Baltimore, Maryland.

His translational/clinical research for the past twenty years has focused on the field of cancer immunology and immunotherapy with special emphasis in B-cell malignancies. He has published more than 130 manuscripts, including seminal publications in top tier journals such as Nature Medicine, Nature Immunology, Immunity, Cancer Cell, Proceedings of the National Academy of Sciences, Journal of Clinical Investigations, Blood, Cancer Research and Journal of Immunology. He has received multiple grants from the Lymphoma Research Foundation (LRF), the National Cancer Institute and biotech/pharmaceutical companies.

Dr. Sotomayor is a member of the Scientific Advisory Board, Lymphoma Research Foundation, member of the Executive Committee of the Mantle Cell Lymphoma Consortium, member of the Science Policy and Government Affairs Committee, American Association for Cancer Research (AACR), Chair, Latin American Regional Advisory Group, International Affairs Committee, AACR, member of the Hematologic Malignancies Task Force at AACR, member Cancer Immunology and Immunotherapy (CIMM) Steering Committee at AACR and a former member, National Cancer Institute, Subcommittee A, Cancer Centers.

FRÉDÉRIC BIEMAR
GAGANDEEP BRAR 
GAGANDEEP BRAR
Assistant Professor of Medicine
Division of Hematology/Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian

KATERINA POLITI 
KATERINA POLITI
Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus‘s lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as an Associate Professor in the Departments of Pathology and Internal Medicine (in the Section of Medical Oncology). Her laboratory is focused on studying the biology of lung cancer and on uncovering mechanisms of resistance to targeted therapies and immunotherapies in this disease. At the Yale Cancer Center, Dr. Politi is a co-leader of the Cancer Signaling Networks Research Program.

KATHERINE BEVER
MANUEL HIDALGO 
MANUEL HIDALGO
Manuel Hidalgo, M.D., Ph.D. is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital. He is also the Hugh E. Luckey Distinguished Professor of Medicine at Weill Cornell Medical Collge. Dr. Hidalgo received his MD degree from the University of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health Science Center in San Antonio. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio, TX. Prior to this position he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to be Director of the Gastrointestinal Oncology Programm at the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor of Oncology. In 2009 he became Director of the Clinical Research Program at the Speanish National Cancer Center and Vicedirector of Translational Research in 2011. In 2015 he became the Chief of the Division of Hematology and Oncology anf Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the used of Avatar mouse models for cancer research and recently contributed to the development and approval of nab-paclitaxel for pancreatic cancer treatmemt. His current work focuses on strategies for personalize medicine and inmmunotherapy in pancreatic cancer.

MARGARET FOTI
MONIKA SAFFORD 
MONIKA SAFFORD
Dr. Monika Safford is John J. Kuiper Professor of Medicine and Chief of the Division of General Internal Medicine at Weill Cornell Medical College. She is a clinician-investigator with clinical expertise in preventive healthcare, treatment of acute and chronic illness and the coordination of care for those with complex diseases. Dr. Safford previously served at University of Alabama at Birmingham (UAB) School of Medicine as the Inaugural Endowed Professor of Diabetes Prevention and Outcomes Research, Assistant Dean for Continuing Medical Education, Associate Director of the Center for Outcomes and Effectiveness Research and Education, and Co-Director of UAB’s T32 Health Services and Comparative Effectiveness Research Training Program. She is an active principal investigator with ongoing support from the National Institutes of Health, Patient Centered Outcomes Research Institute, and industrial sources. Throughout her career as an educator, she has trained and mentored numerous medical students, graduate students, residents, fellows, and junior faculty members. She has chaired national meetings for the Society of General Internal Medicine and the American Diabetes Association for which she serves on a steering committee for an ISTEP medical education initiative and was Co-Chair of the ISTEP Writing Committee. Dr. Safford’s honors include the American Association of Medical Colleges Learning Health System Research Pioneer Award (2013-14), a Gold Honor Society Humanism Program faculty mentor appointment (2012) and multiple awards for Research Excellence from UAB Department of Medicine, including the UAB Department of Medicine Max Cooper Award for Excellence in Research.

RENIER BRENTJENS 
RENIER BRENTJENS
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors.

Conflito de Interesses: JUNO Therapeutics (BMS): Research Funding; Gracell Biotechnologies, Inc.: consultant/advisor.

TODD GOLUB 
TODD GOLUB
Founding Core Member, Chief Scientific Officer, and Director of the Cancer Program at the Broad Institute of MIT and Harvard
Director of the Gerstner Center for Cancer Diagnostics at the Broad Institute
Professor of Pediatrics at Harvard Medical School
Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute


National Speakers

ALESSANDRO LEAL 
ALESSANDRO LEAL
Oncologista Clínico do Hospital Israelita Albert Einstein
Head da Área de Medicina Personalizada do Hospital Israelita Albert Einstein
Co-Founder da Delfi Diagnostics, Inc. (Baltimore, EUA)
PhD em Genômica de Câncer pela Johns Hopkins University (Baltimore, EUA)
Residência em Oncologia Clínica pelo ICESP / HCFMUSP
ALINE LAUDA FREITAS CHAVES 
ALINE LAUDA FREITAS CHAVES
Clinical Oncologist
Director - Grupo Dom ONCologia
President - Brazilian Group of Head and NEck Cancer

Conflito de Interesses: Speaker - MSD, BMS, Danone, Merck Advisory Board: MSD, BMS, DAnone.
ANAMARIA CAMARGO 
ANAMARIA CAMARGO
Biologist with an Undergraduate degree and PhD from the University of São Paulo and a post-doctorate from the Ludwig Institute for Cancer Research. She is currently a researcher and head of the Centre of Molecular Oncology at Hospital Sírio Libanês. She works with cancer genetics and genome.
ANDRÉ FAY 
ANDRÉ FAY
Professor da Escola de Medicina e do Programa de Pós-graduação da PUCRS. Coordenador Médico do Centro de Oncologia Oncoclínicas-Hospital São Lucas da PUCRS. Pesquisador Visitante da Dana-Farber Cancer Institute/Harvard Medical School. Membro do "steering committee" do LACOG-GU. Membro efetivo do comitê de tumores urológicos da SBOC.
ANDRÉIA CRISTINA DE MELO 
ANDRÉIA CRISTINA DE MELO
Graduação em Medicina pela Universidade Federal de Minas Gerais. Doutora em Oncologia pelo INCA (2015). Atualmente é chefe da Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico do INCA, Oncologista do Grupo Oncoclínicas
ANGELICA NOGUEIRA RODRIGUES 
ANGELICA NOGUEIRA RODRIGUES
Post-doctorate at MGH/Harvard University, Professor and researcher at UFMG (Federal University of Minas Gerais). President of the Brazilian Group for Gynaecological Tumours, EVA. Technical Director at DOM Oncology
ARTUR KATZ 
ARTUR KATZ
Head of Clinical Oncology Services at the Centre for Oncology at Hospital Sírio Libanês. Former president of the Brazilian Society of Clinical Oncology (SBOC)
AUGUSTO MOTA 
AUGUSTO MOTA
Títulos e filiações
Membro da Sociedade Brasileira de Oncologia Clínica (SBOC)
Título de especialista em Cancerologia Clínica pela Sociedade Brasileira de Cancerologia
Membro da Sociedade Americana de Oncologia Clínica (ASCO)

Áreas de Interesse
Tumores Gênito-urinários
Tumores de Cabeça e Pescoço
Tumores da mama

Formação profissional
Graduação na Escola Bahiana de Medicina e Saúde Pública (1993)
Residência em Clínica Médica no Hospital das Clínicas da Faculdade Medicina da USP-SP (1994-1995)
Residência em Hematologia e Hemoterapia no Hospital das Clínicas da Faculdade Medicina da USP-SP (1995-1997)
Fellowship em Oncologia Clínica Na Universidade Yale (EUA, 1998-2000)
Doutor em Medicina e Saúde Humana pela Fundação para o Desenvolvimento das Ciências / Fiocruz (2006)
BERNARDO GARICOCHEA 
BERNARDO GARICOCHEA
DR. BERNARDO GARICOCHEA CRM (SP): 47.162 MD at Centre for Oncology at Hospital Sírio Libanês, Bela Vista Branch. Head of Teaching and Research at the Centre for Oncology at Hospital Sírio Libanês. Undergraduate degree in medicine at Pontifícia Universidade Católica do Rio Grande do Sul; Masters degree and PhD from the University of São Paulo; Post-Doctorate in Molecular Biology from Royal Postgraduate Medical School of London; Post-doctorate in Oncological Genetics from Memorial Sloan Kettering Cancer Center - New York.
BRUNO FERRARI 
BRUNO FERRARI
Founder and president of the Administrative Board of Group Oncoclínicas; Technical Director of Group Oncoclínicas, Member of the Clinical Guidelines Committee at ASCO.
CARLOS GIL MOREIRA FERREIRA 
CARLOS GIL MOREIRA FERREIRA
Carlos Gil Ferreira, MD, PhD. Clinical oncologist, doctor in experimental oncology through Vrije Universiteit Medical Center, Amsterdam, Holland. President and scientific director of Instituto Oncoclínicas.
CARLOS H. BARRIOS 
CARLOS H. BARRIOS
Carlos H. Barrios M.D. is Director of the Oncology Research Center at Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS). He is Director of LACOG, Latin American Cooperative Oncology Group, Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine, Florida and physician member of the Oncoclinicas Group..

Dr. Barrios received his medical degree from Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), in Porto Alegre, RS, Brazil. He is Board certified in Internal Medicine being trained at the Hospital de Clínicas, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil and Jackson Memorial Hospital, University of Miami, Miami, Florida. Is also Board Certified in Hematology and Oncology training at Barnes and Jewish Hospitals, Washington University, Saint Louis, Missouri.

Dr. Barrios is member of the Executive Board of the Breast International Group (BIG) and is very interested in clinical research participating in over 250 industry sponsored and academic clinical trials over the last 20 years. He has many abstract presentations in national and international congresses and has contributed significantly in the literature with peer reviewed publications. He has a strong interest in the development of international research collaborations and implementation of cooperative research infrastructures in Latin America. He is cofounder and current director of LACOG (Latin American Cooperative Oncology Group), which congregates more than 100 investigators in more than 70 institutions from 14 different countries in Latin America.
CLARISSA MATHIAS 
CLARISSA MATHIAS
Oncologist at NOB/Oncoclínicas, chair of the International Council of the American Society of Clinical Oncology (ASCO), president of the Brazilian Society of Clinical Oncology (SBOC).
DANIEL HERCHENHORN
DANIELA DORNELLES ROSA 
DANIELA DORNELLES ROSA
- Medical Oncologista at Hospital Moinhos de Vento, Porto Alegre, Brazil;
- MSc and PhD in Medical Sciences at Federal University of Rio Grande do Sul, Porto Alegre, Brazil;
- Post-doctorade at Paterson Institute for Cancer Research, Manchester, UK (supported by CAPES from Brazil);
- Fellowship in Breast Cancer at Jules Bordet Institute, Brussels, Belgium;
- Head of the Brazilian Breast Cancer Study Group (GBECAM).

Conflito de Interesses: •Consultant for: Roche, Novartis, AstraZeneca, Lilly, GSK, Sanofi, Libbs, Eisai, Pfizer, Dr Reddy’s, Amgen •Research funding from: Amgen, Roche, GSK, L’Òreal •Expert testimony for: Roche, Novartis, Pfizer, AstraZeneca, Lilly
DIOGO ASSED BASTOS 
DIOGO ASSED BASTOS
Oncologist specialising in urogenital and genital tract tumors at Cancer Institute of the State of São Paulo (ICESP) and Sírio-Libanês Hospital
DUILIO REIS DA ROCHA FILHO 
DUILIO REIS DA ROCHA FILHO
Doutor em oncologia pelo AC Camargo Cancer Center, Conselheiro Científico do Grupo Brasileiro de Tumores Gastrointestinais, chefe do Serviço de Oncologia Clínica do Hospital Walter Cantídio (UFC-CE)
EMMANUEL DIAS-NETO 
EMMANUEL DIAS-NETO
Undergraduate degree in Biological Sciences from the Federal University of Minas Gerais (1989), Master’s degree in Cellular and Molecular Biology from Fundação Oswaldo Cruz (1994), PhD in Biochemistry and Immunology from the Federal University of Minas Gerais (1997) and Post-doctorate in Cancer Genomics from the Ludwig Institute for Cancer Research (1999). Was a senior researcher at the Ludwig Institute for Cancer Research (up until 2002), vice-director of the Neuroscience Laboratory (LIM-27) at the Psychiatry Institute of the Faculty of Medicine at the University of São Paulo (USP) (up until 2006) and Visiting Professor at the University of Texas, MD Anderson Cancer Center (up until September, 2009). Is currently an adjunct scientist at the International Research Center at AC Camargo Cancer Center, where he manages the Genomic Medicine Laboratory. Is experienced in Molecular and Genomic Biology.
FELIPE ANDREIUOLO
FERNANDO NUNES GALVÃO DE OLIVEIRA 
FERNANDO NUNES GALVÃO DE OLIVEIRA
Fernando Nunes Galvão de Oliveira
Medical Oncologist - CLION/ CAM Group
LACOG GU board of directors
ASCO/ ESMO/ SBOC member
GILBERTO DE CASTRO JUNIOR 
GILBERTO DE CASTRO JUNIOR
Associate Physician for the Clinical Oncology Services at the Institute of Cancer of São Paulo and Attending Physician at the Center of Oncology at Hospital Sírio Libanês, São Paulo - SP. PhD Professor - Discipline of Oncology at the Faculty of Medicine at USP (University of São Paulo).

Conflito de Interesses: Fees for travel, accommodations, expenses, advisory board; speakers‘ bureau; participation in sponsored trials: MSD, AstraZeneca, Roche, BMS, Merck Serono, Amgen, Pfizer, Boehringer Ingelheim
GUSTAVO DOS SANTOS FERNANDES 
GUSTAVO DOS SANTOS FERNANDES
Director General at the Brasilia Unit of Hospital Sírio Libanês. Advanced Clinical Fellow (MSKCC); Former President of the Brazilian Society of Clinical Oncology SBOC (management 2015/2017); Residency in Cancerology at Hospital Sírio-Libanês, São Paulo, Brazil; Residency in General Practice and Haematology at the University of São Paulo (HCMFMUSP); Undergraduate degree in medicine from the Federal University of Paraíba (UFPB).
GUSTAVO FERNANDES GODOY ALMEIDA 
GUSTAVO FERNANDES GODOY ALMEIDA
Oncologia pelo HC de SP
Doutor em oncologia pela USP
Pós-Doc pela Universidade Federal de Pernambuco
Oncologista do Santa Joana Recife (Americas UHG) e do HC de Pernambuco
Professor de Oncologia da Universidade Católica de Pernambuco
Membro da SBOC e da ASCO

Conflito de Interesses: Employment: United Health Group Honoraria: Astellas Pharma, United Medical, Bayer Consulting or Advisory Role: Bristol-Myers Squibb, Bayer, Roche Speakers‘ Bureau: Bayer Travel, Accommodations, Expenses: Bristol-Myers Squibb, Astellas Pharma, Roche, Bayer
GUSTAVO SCHVARTSMAN 
GUSTAVO SCHVARTSMAN
- Medical Oncologist at Hospital Israelita Albert Einstein
- MD by the Federal University of São Paulo
- Medical Oncology Fellowship at The University of Texas MD Anderson Cancer Center
- PhD at Hospital Israelita Albert Einstein
IGOR A. PROTZNER MORBECK 
IGOR A. PROTZNER MORBECK
PROFESSOR OF MEDICINE AT PUC-BRASILIA (PONTIFICAL CATHOLIC UNIVERSITY) AND ONCOLOGIST AT HOSPITAL SIRIO-LIBANES, BRASILIA. HEAD OF THE UROLOGIC TUMOR COMMITTEE AT SBOC (BRAZILIAN SOCIETY OF CLINICAL ONCOLOGY)

Conflito de Interesses: SPEAKER OF ROCHE, MSD, BMS, JANSSEN ADVISORY BOARD FOR MSD, ROCHE, BMS, PFIZER, ASTRA-ZENECA
JOSE BINES 
JOSE BINES
Oncology at northwestern university. MD at the national institute of cancer. Doctorate from the national cancer institute.
LUISA LINA VILLA 
LUISA LINA VILLA
Associate Professor – Department Radiology and Oncology
Faculty of Medicine, University of São Paulo, Cancer Institute of Sao Paulo State (ICESP) - São Paulo, Brazil
LUIZ HENRIQUE ARAUJO 
LUIZ HENRIQUE ARAUJO
Master and Doctor of Medicine. Former Fellow of the American Society of Clinical Oncology. Former Postdoctoral Researcher at Ohio State University. Medical Oncologist and Researcher at the National Cancer Institute, in Mato Grosso do Sul (INCA/MS). Scientific Director of the COI Institute. Medical Associate at Progenética/Pardini Laboratory
MARCELA CROSARA ALVES TEIXEIRA 
MARCELA CROSARA ALVES TEIXEIRA
Dr. Marcela Crosara. Undergraduate in medicine from the Escola Paulista de Medicina - Federal University of São Paulo (UNIFESP). Residency in Oncology at the Institute of Cancer of São Paulo - USP. Worked as associate practician in the gastrointestinal tumors Group at the Institute of Cancer of São Paulo - USP. Worked as principal practician in the Oncology Center of Hospital Sírio-Libanês - Brasilia Unit, specializing in gastrointestinal tract tumors. Currently Head of the Center of Oncology of the DF STAR Hospital/ Rede D'Or Brasilia-DF
MARCELO REIS 
MARCELO REIS
Marcelo Reis é médico e doutor em Química Biológica pela Universidade Federal do Rio de Janeiro. Especialista em genética molecular e genômica do câncer com treinamento no Ludwig Center for Cancer Genetics and Therapeutics da Universidade Johns Hopkins. Atualmente é pesquisador no Instituto D‘Or de Pesquisa e Ensino e seus esforços estão voltados para investigação dos mecanismos moleculares da formação de tumores, visando a descoberta e desenvolvimento de novas estratégias terapêuticas e marcadores moleculares para o diagóstico, prognóstico ou detecção precoce do câncer.
MARIA IGNEZ FREITAS MELRO BRAGHIROLI 
MARIA IGNEZ FREITAS MELRO BRAGHIROLI
Medical Oncologist at the Institute of Cancer of São Paulo and Rede D'Or, Fellowship at Memorial Sloan Kettering Cancer Center - NY in Gastrointestinal Tumors and studying towards a PhD in Oncology at the Faculty of Medicine of the University of São Paulo (FMUSP)

Conflito de Interesses: Estudos clínicos institucionais: Roche, Astra-Zeneca, MSD, BMS Atividades remuneradas Roche, MSD, Bayer, Merck
MARIANE FONTES 
MARIANE FONTES
Clinical Oncology / Genitourinary Tumors – Oncoclínicas Group RJ. Specialization in Uro-Oncology and Drug Development at the Royal Marsden NSH Foundation Trust / Institute of Cancer Research - London (2015-2017). Medical residency in Clinical Oncology at INCA (2010-2013). Member of the Director's Board of SBOC-RJ 2020-2021 (Brazilian Society of Clinical Oncology), Member of LACOG – GU (Latin American Cooperative Oncology Group). Member of the Brazilian Society of Clinical Oncology (SBOC). Member of the American Society of Clinical Oncology (ASCO). Member of European Clinical Oncology Society (ESMO)
MARIANO GUSTAVO ZALIS 
MARIANO GUSTAVO ZALIS
Possui graduação em Biomedicina pela Universidade Federal do Estado do Rio de Janeiro (1983), mestrado em Biofísica - Weizmann Institutte Of Science (1986) e doutorado em Ciências Biológicas (Fisiologia) pela Universidade Federal do Rio de Janeiro (1993) e Harvard School of Public Health. Professor adjunto da Universidade Federal do Rio de Janeiro, na área de Biologia Molecular, Genética humana e de doenças infecciosas desde 1994. Atualmente é diretor de Pesquisa e Desenvolvimento , do Laboratório OC Precision Medicine , Grupo Oncoclínicas
MAURO ZUKIN 
MAURO ZUKIN
Lead at the Thoracic Oncology Program at D'Or Oncology. PhD in Clinical Oncology from INCA.
MAX MANO 
MAX MANO
Max S. Mano MD, PhD, MAS in Medical Leadership
Medical Oncologist, Breast Cancer Group Leader, Grupo Oncoclínicas
Faculty - ESMO Breast Cancer Group
Faculty - SBOC Breast Cancer Group
Faculty - Academy of Leadership Sciences Switzerland (ALSS)
MILENA MAK 
MILENA MAK
Oncologist at Oncology D'Or. Member of the Thoracic and Head and Neck Cancer Oncology Group and the Research Nucleus of the Institute of Cancer of São Paulo. Has an undergraduate degree in Medicine from the Faculty of Medicine at the University of São Paulo (FMUSP). Residency in Clinical Practice through FMUSP and in Clinical Oncology at the Institute of Cancer of São Paulo/HC-FMUSP. She is currently a Doctorate student at the Oncology program at FMUSP and was a postdoctoral fellow at the Thoracic/Head and neck Medical Oncology, The University of Texas, MD Anderson Cancer Center. Member of ASCO (American Society of Clinical Oncology), SBOC (Brazilian Society of Clinical Oncology), GBOT (Brazilian Group of Thoracic Oncology).
OLAVO FEHER 
OLAVO FEHER
Management at Sarcoma, Melanoma and Upper Urinary Tract of the Central Nervous System - ICESP (Institute of Cancer of São Paulo). Attending Physician - Center of Oncology at Hospital Sírio Libanes.
PAULO CAMPREGHER 
PAULO CAMPREGHER
Hematologist and Clinical Pathologist, responsible for molecular diagnostics in oncology and hematology at the department of diagnostic medicine at Albert Einstein, researcher at IEP Albert Einstein and head of the course 'Base Genomics of Cancer and Precision Oncology' at Hospital Albert Einstein.
PAULO MARCELO GEHM HOFF 
PAULO MARCELO GEHM HOFF
A doctor through the Universidade de Brasília (1991); PHD and associate professor of Oncology at Universidade de São Paulo Medical School, where he is a Full Professor; Fellowship in Hematology and Oncology at MD Anderson Cancer Center. Currently General Director of the Instituto do Câncer de São Paulo “Octávio Frias de Oliveira” and member of the Board of Directors at ASCO and the Hospital das Clínicas.
RODRIGO DIENSTMANN 
RODRIGO DIENSTMANN
Medical Director of Oncoclínicas Precision Medicine e Big Data, São Paulo. And as scientific head of the research group Oncology Data Science at Vall d‘Hebron Institute of Oncology, Barcelona.

Conflito de Interesses: RD has declared advisory role for Roche, AstraZeneca and Boehringer Ingelheim, has received a speaker’s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Merck Sharp & Dohme, and research grants from Merck and Pierre Fabre.
RODRIGO PEREZ PEREIRA 
RODRIGO PEREZ PEREIRA
Oncologista Clínico
Líder de Práticas Assistenciais em Tumores Cutâneos Grupo Oncoclínicas
Pesquisador na Unidade de Pesquisa Clínica em Oncologia do Hospital de Clínicas de Porto Alegre
RODRIGO RAMELLA MUNHOZ 
RODRIGO RAMELLA MUNHOZ
Medical Oncologist specializing in cutaneous tumors and sarcomas at Hospital Sírio Libanês and the Institute of Cancer of São Paulo.

Conflito de Interesses: Research involvement: BMS/MSD/Sanofi/Roche/Novartis Honoraria: MSD/Novartis/BMS/Bayer/Sanofi Advisory role: Sanofi/BMS/Bayer/Roche
ROMUALDO BARROSO DE SOUSA 
ROMUALDO BARROSO DE SOUSA
Romualdo Barroso-Sousa, MD, PhD
Associate Physician, Translational Research Coordinator
Oncology Center, Hospital Sírio-Libanês Brasília, Brazil
RUI REIS 
RUI REIS
Dean of Graduate Studies - Barretos Cancer Hospital. Executive and Scientific Director - Teaching and Research Institute, Barretos Cancer Hospital. Invited Assistant Professor - School of Medicine, University of Minho, Portugal.
SERGIO SIMON 
SERGIO SIMON
Universidade de SP Medical School, 1973; specialty in Internal Medicine, Hematology and Clinical Oncology in the United States 1974-1980; doctorate at the Universidade de São Paulo, 2003; assistant professor of Oncology, UNIFESP 2008-2013; clinical oncologist at Hospital Israelita Albert Einstein and at Centro Paulista de Oncologia; member of SBOC, ASCO and ESMO.
TOMÁS REINERT 
TOMÁS REINERT
Oncologista clínico - Oncoclinica Porto Alegre e PUCRS
Doutor em Ciencias Médicas pela UFRGS
Diretor Cientifico do Centro de Pesquisa da Serra Gaucha (CEPESG)
Ex- visiting research fellow - Washington University at St Louis
VERIDIANA P. D. CAMARGO 
VERIDIANA P. D. CAMARGO
Attending Clinical Oncologist at D'Or Oncology. Assistant Clinical Oncologist at ICESP - Institute of Cancer of São Paulo. Former Research fellow of Memorial Sloan Kettering Cancer Center at the Sarcoma Center 2008.
WILLIAM N. WILLIAM JR 
WILLIAM N. WILLIAM JR
MD from the Faculty of Medicine of the University of São Paulo (FMUSP), Medical Director of Clinical Oncology and Hematology of the BP Hospital, Beneficência Portuguesa de São Paulo and Adjunct Professor Associate at MD Anderson Cancer Center, USA.


PROMOTED BY




MANAGEMENT


Diamond Sponsors

Gold Sponsors

Silver Sponsors